{"id":2286,"date":"2025-01-06T14:56:00","date_gmt":"2025-01-06T11:56:00","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2286"},"modified":"2025-03-07T15:30:18","modified_gmt":"2025-03-07T12:30:18","slug":"santhera-enters-into-supply-and-distribution-agreement-for-agamree-vamorolone-with-clinigen-group","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/santhera-enters-into-supply-and-distribution-agreement-for-agamree-vamorolone-with-clinigen-group\/","title":{"rendered":"Santhera firma un acuerdo de suministro y distribuci\u00f3n de AGAMREE (vamorolone) con Clinigen Group"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals anuncia la firma de un acuerdo exclusivo con Clinigen Group para gestionar el suministro y la distribuci\u00f3n de AGAMREE\u00ae (vamorolone) en pa\u00edses donde el producto no est\u00e1 disponible comercialmente.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals y Clinigen Group anuncian que han firmado un acuerdo de suministro y distribuci\u00f3n para AGAMREE en pa\u00edses donde el producto actualmente no puede obtenerse comercialmente a trav\u00e9s de Santhera o uno de sus socios de distribuci\u00f3n actuales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El acuerdo permitir\u00e1 el acceso a AGAMREE caso por caso para pacientes con distrofia muscular de Duchenne (DMD) en situaciones en las que el m\u00e9dico tratante considere que no existen alternativas adecuadas y las regulaciones lo permitan. Este acuerdo permite a Santhera recibir la mayor parte de los ingresos generados por el suministro del producto en estos pa\u00edses adicionales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.santhera.com\/assets\/files\/press-releases\/2025-01-06-Santhera_Clinigen_e-FINAL.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Leer m\u00e1s<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE\u00ae (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,111,41,43],"class_list":["post-2286","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-clinigen-group","tag-santhera","tag-vamorolone"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=2286"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2286\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/2287"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=2286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=2286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=2286"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}